Radiopharmaceuticals: A Guide to Pet/CT and Pet/MRI
Calabria, Ferdinando, Schillaci, Orazio
- 出版商: Springer
- 出版日期: 2024-08-30
- 售價: $5,810
- 貴賓價: 9.5 折 $5,520
- 語言: 英文
- 頁數: 344
- 裝訂: Hardcover - also called cloth, retail trade, or trade
- ISBN: 3031541952
- ISBN-13: 9783031541957
海外代購書籍(需單獨結帳)
相關主題
商品描述
The book is a practical and concise guide to PET tracers actually useful for PET/CT and PET/MR imaging.
Gaining knowledge on radiopharmaceuticals is often difficult, since their features can be only found in single original journal articles.This book aims to present to the reader, in one single place, clinical features, indications and future trends for PET imaging with a large amount of tracers. While 18F-FDG still remains the miliar stone across PET tracer, new emerging fields of application of PET imaging are consolidated by using disease specific tracers in specific clinical settings.
Each chapter is focused on a single tracer or on a group of similar tracers. The basis and structure of the chapters is the same throughout the book: essential information on synthesis and in vivo distribution of a tracer, clinical cases, eloquently showing clinical indications and usefulness, future trends, scientific literature.
Featuring over 30 radiopharmaceuticals and 240 clinical cases, the 3rd edition has been enriched with additional chapters on the clinical indications and/or common pitfalls for 18F-fluciclovine PET/CT in prostate cancer imaging and for 18F-MISO in PET tumor hypoxia imaging, as well as applications and future directions for 18F-FES and other PET radiopharmaceuticals.
All other chapters of the previous edition have been revised and updated, in particular those chapters covering 18F-DOPA, radiolabeled choline, and 18F-NAF, due to emerging clinical applications for these tracers, 18F-choline for imaging of parathyroid adenoma and 18F-DOPA for restaging of medullary thyroid cancer.
The book will be an invaluable guide for professionals and residents in nuclear medicine, radiology, oncology.
商品描述(中文翻譯)
這本書是一本實用且簡潔的指南，專門介紹PET/CT和PET/MR影像學中實際有用的PET示踪劑。
由於放射藥物的特性通常只能在單一原始期刊文章中找到，因此獲取有關放射藥物的知識往往很困難。本書旨在將臨床特徵、適應症和PET影像學中大量示踪劑的未來趨勢呈現給讀者。儘管18F-FDG仍然是PET示踪劑的里程碑，但使用特定疾病示踪劑在特定臨床設置中確立了PET影像學的新興應用領域。
每個章節都專注於單一示踪劑或一組相似的示踪劑。整本書的章節基礎和結構都是相同的：示踪劑的合成和體內分佈的基本信息，臨床案例，生動地展示臨床適應症和用途，未來趨勢，科學文獻。
第三版增加了關於18F-fluciclovine PET/CT在攝護腺癌影像學中的臨床適應症和常見問題，以及18F-MISO在PET腫瘤缺氧影像學中的應用和未來方向的其他章節，共涵蓋了30多種放射藥物和240個臨床案例。
上一版的所有其他章節都經過了修訂和更新，特別是那些涵蓋18F-DOPA、放射性標記的膽鹼和18F-NAF的章節，因為這些示踪劑在臨床應用中出現了新的應用，18F-choline用於甲狀旁腺腺瘤的影像學和18F-DOPA用於髓樣甲狀腺癌的再分期。
這本書將對核醫學、放射學和腫瘤學的專業人士和住院醫師非常有價值。
作者簡介
Dr. Ferdinando Calabria graduated with a degree in Medicine in 2005 and specialized in Nuclear Medicine in 2009 at the University of Rome "Tor Vergata." His specific scientific interest is in deepening our knowledge of the physio-pathological features of PET radiopharmaceuticals bio-distribution in order to verify further diagnostic applications. Another topic is the evaluation of the potential added value of hybrid imaging with SPECT/CT and PET/CT scanners. Since 2010, he has been researcher, focusing the attention on prostate cancer imaging with PET/CT and potential applications of PET/MRI in neurology and neuro-oncology, particularly at the Italian National Research Council, using a multidisciplinary network approach. He is currently exploring the role of advanced hybrid imaging with SPECT/CT and PET/CT in oncology and neurology, at the national public Hospital "Mariano Santo" in Cosenza, Italy. The author of over 50 scientific papers listed in PubMed, he has also served as a reviewer for the major specialized scientific journals of nuclear medicine and radiology.
Prof. Orazio Schillaci graduated with a degree in Medicine in 1990 and specialized in Nuclear Medicine in 19942 at the University of Rome "La Sapienza." He began his scientific work at the University of L'Aquila: during this important period, Schillaci started exploring molecular imaging, with an emphasis on SPECT for neuroendocrine tumors. After a research stay in California, USA, he became a Professor of Nuclear Medicine at the University of Rome "Tor Vergata" in 2001. Since 2008 he has led the School of Specialization in Nuclear Medicine and, since 2013, has been Director of the School Of Medicine at the "Tor Vergata" University Hospital in Rome. The author of more than 220 scientific articles listed in PubMed, his current research interest is in the development of novel PET radiopharmaceuticals and their potential clinical applications in oncology, neurology, cardiology and infectious disease, within a network involving several Italian and European institutions. He is also the former President of the Italian Association of Nuclear Medicine.
作者簡介(中文翻譯)
Dr. Ferdinando Calabria於2005年獲得醫學學位，並於2009年在羅馬大學'Tor Vergata'專攻核醫學。他的特定科學興趣在於深入研究PET放射藥物的生物分佈的生理病理特徵，以驗證進一步的診斷應用。另一個主題是評估SPECT/CT和PET/CT掃描儀的混合成像的潛在附加價值。自2010年以來，他一直是一名研究員，專注於PET/CT對攝護腺癌成像以及PET/MRI在神經學和神經腫瘤學中的潛在應用，特別是在意大利國家研究委員會，使用多學科網絡方法。他目前正在探索SPECT/CT和PET/CT在腫瘤學和神經學中的先進混合成像的角色，在意大利科森扎的國家公立醫院'Mariano Santo'。作為PubMed列出的50多篇科學論文的作者，他還擔任核醫學和放射學主要專業科學期刊的審稿人。
Prof. Orazio Schillaci於1990年獲得醫學學位，並於1994年在羅馬大學'La Sapienza'專攻核醫學。他在拉奎拉大學開始了他的科學工作：在這一重要時期，Schillaci開始探索分子影像學，尤其是神經內分泌腫瘤的SPECT。在美國加利福尼亞州進行研究期間，他於2001年成為羅馬大學'Tor Vergata'的核醫學教授。自2008年以來，他一直領導著核醫學專業學校，並自2013年起擔任羅馬'Tor Vergata'大學醫院醫學學院的院長。作為PubMed列出的220多篇科學文章的作者，他目前的研究興趣在於開發新型PET放射藥物及其在腫瘤學、神經學、心臟病學和傳染病學中的潛在臨床應用，涉及多個意大利和歐洲機構的網絡。他還是意大利核醫學協會的前任主席。
